Highest-materiality recent filing
Renalytix reverts to foreign private issuer SEC filing status effective Jan 1, 2025
Company determined it qualifies as FPI as of Dec 31, 2024; will cease domestic issuer filings.
Renalytix announces all 9 resolutions passed at 2024 AGM
All resolutions passed with strong support; Resolution 1 (adopt accounts) received 99.86% votes for.
Renalytix raises £11.6M in private placement and restructures $11.7M convertible bonds
Gross proceeds of £2.16M from first tranche (24M shares) and £9.43M from second tranche (104.7M shares) at £0.09 per share.
Dan Levangie resigned as Non-Executive Director effective Oct 31, 2024, citing no disagreement.
Renalytix launches £10M placing, restructures debt, plans Nasdaq delisting
Minimum £10M gross raised at 9p/share; first tranche of £2.1M closes Oct 9, second tranche conditional on shareholder vote.
Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market
Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.
Renalytix repays $1.06M of convertible bond with shares and ADSs
Issued 2.275M ordinary shares and 4.641M ADSs to settle $1.06M principal and interest due July 7, 2024.
Renalytix replaces auditor; EY out, CohnReznick in for FY2024
Audit committee dismissed EY effective June 18, 2024; engaged CohnReznick LLP as new auditor for FY ending June 30, 2024.
Renalytix appoints CohnReznick as auditor, dismisses EY after cost review
Audit committee selected CohnReznick as new independent registered public accounting firm for FY ending June 30, 2024, effective June 19, 2024.
Renalytix receives Nasdaq delisting notice; intends to appeal by June 28
Nasdaq determined company did not regain compliance with minimum bid price ($1.00) and MVLS ($50M) by June 19, 2024.
Medicare finalizes coverage for Renalytix's kidneyIntelX.dkd at $950/test effective Aug 1, 2024
Medicare issued final Local Coverage Determination (LCD) for kidneyIntelX.dkd; effective dates of service on/after August 1, 2024.
Appoints Joel Jung as Interim CFO with $8k/month salary and 60k options
Interim CFO Joel Jung receives $8,000 monthly base salary under consulting agreement.
CFO O. James Sterling resigns effective May 24; Joel R. Jung appointed interim CFO
CFO O. James Sterling resigned May 24, 2024; will remain through transition period ending June 10, 2024.
Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated
Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.
Renalytix enters $15M at-the-market equity offering with H.C. Wainwright
Company may sell ADSs with aggregate offering price up to $15M on Nasdaq through H.C. Wainwright.
Renalytix closes second tranche of private placement, raises ~$7M gross
Second Tranche of 26,815,841 ordinary shares at £0.20 each closed on April 24, 2024, following shareholder approval.
Renalytix president McLain resigns, Howard Doran appointed; equity offering expanded
Thomas McLain resigns as President effective April 30, 2024; severance includes 6 months base salary ($450K) and accelerated vesting of 12 months of options.
Renalytix repays $1.06M of convertible bonds with ADSs; outstanding principal now $12.72M
Issued 1,818,081 ADSs (3,636,162 ordinary shares) on April 11, 2024 to settle $1.06M of principal and interest due April 7, 2024.
Renalytix raises $1M in registered direct offering at $0.375/share, with option for up to $3.9M
Issued 2,666,667 ordinary shares at $0.375 each for gross proceeds of approximately $1.0 million.
Renalytix raises up to $4M in registered direct offering with DB Capital Partners
Initial tranche of $1.0M at $0.75 per ADS ($0.375 per ordinary share) closing by April 11.
Renalytix amends bond agreement with CVI, adds beneficial ownership cap and payment deferral rights
Amendment with CVI Investments adds a 9.99% beneficial ownership limitation on bondholder's ordinary shares.
KidneyIntelX included in final KDIGO 2024 guideline for CKD risk prediction
KidneyIntelX recommended for predicting CKD progression in stages G1-G3 per KDIGO 2024 guideline released March 13.
Renalytix raises ~$12M via two-tranche equity placing at £0.20/share
First tranche of 19,986,031 shares closes March 14, 2024, raising ~$5M gross.
Daniel Levangie, tendered his resignation from the Company's Board of Directors and all committees effective on October 31, 2024.
announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.
On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).
On April 17, 2024, Thomas McLain notified the Company that he will resign as President of the Company, effective April 30, 2024
On April 23, 2024, the Company’s Board of Directors (the “ Board ”) appointed Howard Doran, currently the Company’s Chief Business Officer, to serve as the Company’s President, effective as of April 30, 2024.
Max materiality 1.00 · Median 0.55 · Most common event other_material